Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
Angiotensin II-receptor antagonists: An overview
American Journal of Health-System Pharmacy, 2000 Angiotensin II (AT-II)-receptor antagonists are reviewed. Research focused on blocking the renin-angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors, which are effective in the treatment of hypertension but are associated with a high frequency of cough and other adverse effects.
Dina, Raquel, Jafari, Mahtab
openaire +5 more sources
Comparison of angiotensin II receptor antagonists [PDF]
European Journal of Clinical Investigation, 2001 Nonpeptide orally active angiotensin II type 1 (AT1) receptor antagonists are the most specific means presently available to block the renin‐angiotensin enzymatic cascade. Six of these drugs have already been licensed in Europe and in the United States for the treatment of high blood pressure, and additional candidates are in the pipeline.
Wilhelm Kirch, B. Horn, J. Schweizer
openaire +3 more sources
Acute kidney injury: an acceptable risk of treatment with renin-angiotensin system blockade in primary care? [PDF]
, 2015 Background: Use of renin-angiotensin system (RAS) blockade has become increasingly widespread driven by evidence-based guidance. There is concern about the role of these agents in the genesis of avoidable acute kidney injury (AKI).
Bellomo R +7 more
core +2 more sources
Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma [PDF]
, 2002 No abstract ...
Bray, C.A., Hole, D.J., Mackie, R.M.
core +2 more sources
Accurate Evaluation on the Interactions of SARS-CoV-2 with Its Receptor ACE2 and Antibodies CR3022/CB6 [PDF]
CHIN.PHYS.LETT. Vol.38, No.1(2021)018701 Express Letter, 2021 The spread of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become a global health crisis. The binding affinity of SARS-CoV-2 (in particular the receptor binding domain, RBD) to its receptor angiotensin converting enzyme 2 (ACE2) and the antibodies is of great importance in ...
arxiv +1 more source
The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment [PDF]
, 2003 National surveys suggest that treatment of heart failure in daily practice differs from guidelines and is characterized by underuse of recommended medications.
Aguilar, JC +17 more
core +7 more sources
Український Журнал Нефрології та Діалізу, 2014 Damage of renal function and dynamics of dyslipidemia in patients with type 2 diabetes mellitus with insufficient glycemic compensation under condition of correction of hypertension with angiotensin II receptor antagonists Introduction.
N.O. Pertseva
doaj +1 more source
The orphan receptor GPR35 contributes to angiotensin II–induced hypertension and cardiac dysfunction in mice [PDF]
, 2018 BACKGROUND: The orphan receptor G protein–coupled receptor 35 (GPR35) has been associated with a range of diseases, including cancer, inflammatory bowel disease, diabetes, hypertension, and heart failure.
Divorty, Nina +3 more
core +1 more source
Eprosartan mesylate, an angiotensin II receptor antagonist [PDF]
Acta Crystallographica Section E Structure Reports Online, 2011 The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carb-oxy-benz-yl)-5-[(E)-2-carb-oxy-3-(thio-phen-2-yl)prop-1-en-yl]-1H-imidazol-3-ium methane-sulfonate}, C(23)H(25)N(2)O(4)S(+)·CH(3)O(3)S(-), one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in ...
Xiu-Rong Hu +3 more
openaire +3 more sources